Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials
International Forum of Allergy & Rhinology · 2024
DOI: 10.1002/alr.23322 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Eli O Meltzer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Omalizumab, Nasal Polyps, Sinusitis, Rhinitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech, Inc., Genentech.
Abstract (Originalsprache)
Background
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) have high incidence of sleep impairment. We evaluated the impact of omalizumab treatment on sleep characteristics and associated health status in patients with CRSwNP.
Methods
Prespecified exploratory analysis assessed outcomes from patients included in the POLYP 1 and POLYP 2 phase 3 clinical trials and the open‐label extension. Sleep was assessed by the sleep domain of the Sino‐Nasal Outcome Test‐22 (SNOT‐22; MCID > 4 in patients with CRS) and the Medical Outcomes Study Sleep Scale (MOS‐Sleep). Health status was assessed by Healthy Days Core Module (HDCM) and sinonasal‐specific Patient Global Impression of Change (PGIC).
Results
Omalizumab improved sleep as assessed by the SNOT‐22 sleep domain. At week 24, adjusted mean (95%CI) SNOT‐22 sleep scores had reduced from baseline by −8.5 (–9.9 to –7.1) with omalizumab versus –2.7 (–4.1 to –1.3) with placebo. At week 52 (all patents on OMA), adjusted mean (95%CI) SNOT‐22 sleep scores had reduced from baseline by −10.1 (–11.4 to –8.7) with omalizumab. Improvements were observed in all eight items of the SNOT‐22 sleep domain: difficulty falling asleep, fatigue, frustration/restlessness/irritability, lack good night's sleep, reduced concentration, reduced productivity, wake up tired, and wake up at night. In addition, omalizumab improved six of eight sleep outcomes on the MOS‐Sleep scale. There were concurrent improvements in HDCM and PGIC.
Conclusion
Omalizumab improved sleep and self‐reported health status in patients with CRSwNP. This contributes to evidence that omalizumab provides value for patients beyond the reduction of sinonasal symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, University of California, San Diego, La Jolla, California, USA.
- Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.
- Genentech, Inc., South San Francisco, California, USA.
- Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.
Förderung
- Genentech, Inc.
- Genentech
Zitieren
APA
Meltzer, E. O., Mullol, J., Ko, J., Saenz, R., Steinke, J. W., Millette, L. A., & Gevaert, P. (2024). Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23322
Vancouver
Meltzer EO, Mullol J, Ko J, Saenz R, Steinke JW, Millette LA, et al. Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23322
BibTeX
@article{Meltzer2024,
author = {Meltzer, Eli O and Mullol, Joaquim and Ko, Jinnie and Saenz, Rebecca and Steinke, John W and Millette, Lauren A and Gevaert, Philippe},
title = {Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
doi = {10.1002/alr.23322}
}
EUVIMED